This post was originally published on this site
The U.K.’s Competition and Markets Authority has opened an investigation into the acquisition of Spark Therapeutics Inc. by Roche Holding AG.
The regulator said it is looking into whether the deal will result in a substantial lessening of competition, and has set Dec. 16 as its deadline to decide whether it will continue the investigation.
Roche ROG, +0.03% RO, +0.35% said it agreed to buy the Philadelphia biotechnology company ONCE, +0.78% in February in a bid to expand its presence in hemophilia treatment.
